DICHLORPHENAMIDE

Post-LOE

dichlorphenamide

Rising

ANDAORALTABLET

Approved

Nov 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

DICHLORPHENAMIDE (dichlorphenamide) by Rising is carbonic anhydrase inhibitors [moa]. Approved for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, related variants (). First approved in 2025.

Drug data last refreshed 13h ago

$0.0BPart D

Mechanism of Action

Carbonic Anhydrase Inhibitors

Pharmacologic Class:

Carbonic Anhydrase Inhibitor

Indications (3)

primary hyperkalemic periodic paralysis primary hypokalemic periodic paralysis

Worked on DICHLORPHENAMIDE at Rising? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.